Meeting
2019 ASCO Annual Meeting
A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.
Authors
Ambika Parmar
Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
Ambika Parmar , Marina Richardson , Beate Sander , Susanna Y. Cheng , Kelvin K. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6639)
DOI
10.1200/JCO.2019.37.15_suppl.6639
Abstract #
6639
Poster Bd #
330
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
First Author: Alessio Cortellini
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.
First Author: Mavis Obeng-Kusi
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of FDA label change on immunotherapy for metastatic urothelial cancer (mUC) and subsequent changes in mortality.
First Author: Daniel Vader